Equities research analysts forecast that EXACT Sciences Co. (NASDAQ:EXAS) will report earnings per share of ($0.28) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for EXACT Sciences’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.31). EXACT Sciences reported earnings per share of ($0.34) during the same quarter last year, which suggests a positive year-over-year growth rate of 17.6%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, February 22nd.

On average, analysts expect that EXACT Sciences will report full-year earnings of ($1.08) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($1.04). For the next year, analysts anticipate that the company will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.84) to ($0.44). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover EXACT Sciences.

Several analysts have issued reports on the company. William Blair restated a “buy” rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Robert W. Baird increased their target price on EXACT Sciences from $49.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 31st. Jefferies Group raised their price objective on EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Benchmark restated a “buy” rating and set a $60.00 price objective (up previously from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Finally, Leerink Swann set a $67.00 price objective on EXACT Sciences and gave the stock a “buy” rating in a research note on Friday. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $52.84.

In other news, insider Kevin T. Conroy sold 134,057 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kevin T. Conroy sold 110,439 shares of the company’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $50.49, for a total transaction of $5,576,065.11. Following the completion of the transaction, the insider now directly owns 940,491 shares in the company, valued at approximately $47,485,390.59. The disclosure for this sale can be found here. Insiders sold a total of 662,694 shares of company stock worth $35,934,015 in the last 90 days. Company insiders own 4.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lord Abbett & CO. LLC raised its stake in EXACT Sciences by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock worth $83,357,000 after buying an additional 875,527 shares in the last quarter. FMR LLC increased its stake in shares of EXACT Sciences by 32.7% during the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after purchasing an additional 571,796 shares in the last quarter. Frontier Capital Management Co. LLC increased its stake in shares of EXACT Sciences by 163.0% during the third quarter. Frontier Capital Management Co. LLC now owns 916,713 shares of the medical research company’s stock valued at $43,196,000 after purchasing an additional 568,144 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of EXACT Sciences by 82.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock valued at $62,499,000 after purchasing an additional 539,160 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of EXACT Sciences by 95.8% during the third quarter. Canada Pension Plan Investment Board now owns 930,000 shares of the medical research company’s stock valued at $43,822,000 after purchasing an additional 455,000 shares in the last quarter. Institutional investors and hedge funds own 83.12% of the company’s stock.

Shares of EXACT Sciences (NASDAQ:EXAS) traded up $1.34 during midday trading on Friday, reaching $45.90. The company had a trading volume of 2,981,300 shares, compared to its average volume of 3,402,787. EXACT Sciences has a 1 year low of $18.50 and a 1 year high of $63.60. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $5,630.00, a PE ratio of -41.18 and a beta of 0.58.

WARNING: “EXACT Sciences Co. (EXAS) Expected to Post Earnings of -$0.28 Per Share” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/12/exact-sciences-co-exas-expected-to-post-earnings-of-0-28-per-share.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.